• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

泰国女学生接种二价 HPV 疫苗(佳达修®)一剂或两剂的社区干预效果研究。

A community intervention effectiveness study of single dose or two doses of bivalent HPV vaccine (CERVARIX®) in female school students in Thailand.

机构信息

Division of Vaccine Preventable Diseases, Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.

International Vaccine Institute, Seoul, Republic of Korea.

出版信息

PLoS One. 2022 Apr 28;17(4):e0267294. doi: 10.1371/journal.pone.0267294. eCollection 2022.

DOI:10.1371/journal.pone.0267294
PMID:35482803
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9049519/
Abstract

Human papillomavirus (HPV) is a common infection principally spread through sexual activity. Most HPV infections are asymptomatic and resolve spontaneously. However, persistent infection may progress to cervical cancer. Highly efficacious HPV vaccines have been available since 2006, yet uptake into national programs has been slow in part due to cost. WHO guidelines call for a two-dose (0,6 month) schedule for girls 9-14 years of age. Post-hoc analyses of randomized trials have found high vaccine effectiveness following a single dose of vaccine. In order to provide additional data on the potential impact of single dose HPV vaccination in a real-world setting, we are conducting an effectiveness study among Thai schoolgirls. This is an observational study of a single dose (SD) or two doses (2D) of the bivalent HPV vaccine CERVARIX® (GlaxoSmithKline plc.) administered in a school-based program to 8-9,000 Grade 8 female students in two provinces of Thailand beginning in 2018; one province is assigned the SD, and the other the standard 2D regimen. The reduction in HPV vaccine-type prevalence will be assessed in each province two and four years after vaccination by comparing HPV prevalence in urine samples obtained through cross-sectional surveys of the immunized grade cohort as they age and compared to a historical "baseline" HPV prevalence of same age students.

摘要

人乳头瘤病毒(HPV)是一种常见的感染,主要通过性活动传播。大多数 HPV 感染是无症状的,会自行消退。然而,持续感染可能会进展为宫颈癌。自 2006 年以来,高效的 HPV 疫苗已经问世,但由于成本原因,在国家计划中的接种率一直很慢。世卫组织指南呼吁为 9-14 岁的女孩接种两剂(0、6 个月)疫苗。随机试验的事后分析发现,一剂疫苗接种后疫苗具有很高的有效性。为了提供更多关于在现实环境中单剂量 HPV 疫苗接种潜在影响的数据,我们正在泰国女学生中开展一项疫苗有效性研究。这是一项观察性研究,在泰国两个省的学校计划中,对 8000 至 9000 名 8 年级的女学生接种一剂(SD)或两剂(2D)二价 HPV 疫苗 CERVARIX®(葛兰素史克公司);其中一个省分配 SD,另一个省分配标准的 2D 方案。在接种疫苗两年和四年后,通过比较免疫接种年级队列的尿液样本中的 HPV 流行率,评估每个省的 HPV 疫苗型流行率,这些样本是通过对年龄较大的免疫学生进行横断面调查获得的,并与同年龄学生的历史“基线”HPV 流行率进行比较。

相似文献

1
A community intervention effectiveness study of single dose or two doses of bivalent HPV vaccine (CERVARIX®) in female school students in Thailand.泰国女学生接种二价 HPV 疫苗(佳达修®)一剂或两剂的社区干预效果研究。
PLoS One. 2022 Apr 28;17(4):e0267294. doi: 10.1371/journal.pone.0267294. eCollection 2022.
2
Effectiveness of HPV vaccine as part of national immunization program for preventing HPV infection in Thai schoolgirls after seven years post-vaccination.HPV 疫苗作为泰国全国免疫计划的一部分,在接种疫苗后 7 年对泰国女校学生预防 HPV 感染的效果。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2392330. doi: 10.1080/21645515.2024.2392330. Epub 2024 Sep 6.
3
Impact of one and two human papillomavirus (HPV) vaccine doses on community-level HPV prevalence in South African adolescent girls: study protocol and rationale for a pragmatic before-after design.南非少女人群中 HPV 流行率的社区水平:单剂和两剂人乳头瘤病毒(HPV)疫苗接种效果的研究方案和实用前后设计的原理。
BMJ Open. 2022 Feb 10;12(2):e059968. doi: 10.1136/bmjopen-2021-059968.
4
Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial.评估含人乳头瘤病毒疫苗一剂或两剂的双盲随机非劣效性临床试验的原理和设计:哥斯达黎加 ESCUDDO 试验。 **注**:该临床试验旨在评估含人乳头瘤病毒疫苗一剂或两剂的免疫效果,通过双盲随机非劣效性设计,以评估疫苗的有效性。
Vaccine. 2022 Jan 3;40(1):76-88. doi: 10.1016/j.vaccine.2021.11.041. Epub 2021 Nov 29.
5
Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study.6 年随访青少年斐济女孩接种 1、2 或 3 剂四价人乳头瘤病毒(HPV)疫苗后的抗体持续应答,以及随后接种一剂二价 HPV 疫苗的应答情况:一项前瞻性队列研究。
Clin Infect Dis. 2017 Apr 1;64(7):852-859. doi: 10.1093/cid/ciw865.
6
The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan.在台湾,九价人乳头瘤病毒疫苗与二价人乳头瘤病毒疫苗国家免疫规划的临床和经济影响。
Value Health Reg Issues. 2022 Nov;32:79-87. doi: 10.1016/j.vhri.2022.06.006. Epub 2022 Sep 15.
7
Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda.在乌干达一项二价HPV-16/18疫苗(希瑞适®)试点项目开展5.5年后,与未接种疫苗的年轻女性相比,接种疫苗的年轻女性中疫苗型HPV-16/18感染的基因流行率显著降低。
PLoS One. 2016 Aug 2;11(8):e0160099. doi: 10.1371/journal.pone.0160099. eCollection 2016.
8
Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial.一剂人乳头瘤病毒疫苗与两剂或三剂在坦桑尼亚女孩中的免疫原性和安全性比较(DoRIS):一项开放标签、随机、非劣效性试验。
Lancet Glob Health. 2022 Oct;10(10):e1473-e1484. doi: 10.1016/S2214-109X(22)00309-6.
9
Long-term effectiveness of human papillomavirus vaccines among adult women: A real-world scenario.成人女性中 HPV 疫苗的长期有效性:现实情况。
Vaccine. 2022 Mar 18;40(13):1968-1976. doi: 10.1016/j.vaccine.2022.02.042. Epub 2022 Feb 18.
10
Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.不同人乳头瘤病毒(HPV)疫苗类型及接种程序对预防女性和男性HPV相关疾病的比较。
Cochrane Database Syst Rev. 2019 Nov 22;2019(11):CD013479. doi: 10.1002/14651858.CD013479.

引用本文的文献

1
Community intervention of a single-dose or 2-dose regimen of bivalent human papillomavirus vaccine in schoolgirls in Thailand: vaccine effectiveness 2 years and 4 years after vaccination.泰国在校女生接种二价人乳头瘤病毒疫苗单剂或 2 剂方案的社区干预:接种疫苗后 2 年和 4 年的疫苗效力。
J Natl Cancer Inst Monogr. 2024 Nov 1;2024(67):346-357. doi: 10.1093/jncimonographs/lgae036.
2
Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to multidose vaccination regimens or no vaccination: An updated systematic review of evidence from clinical trials.单剂量人乳头瘤病毒疫苗与多剂量接种方案或未接种疫苗相比的有效性和免疫原性:来自临床试验证据的最新系统评价
Vaccine X. 2024 Apr 16;19:100486. doi: 10.1016/j.jvacx.2024.100486. eCollection 2024 Aug.
3
Estimating human papillomavirus vaccine efficacy from a single-arm trial: proof-of-principle in the Costa Rica Vaccine Trial.从单臂试验估计人乳头瘤病毒疫苗的功效:哥斯达黎加疫苗试验的原理证明。
J Natl Cancer Inst. 2023 Jul 6;115(7):788-795. doi: 10.1093/jnci/djad064.
4
Prevalence of HPV infection among Thai schoolgirls in the north-eastern provinces in 2018: implications for HPV immunization policy.2018年泰国东北部省份女学生人乳头瘤病毒(HPV)感染率:对HPV免疫政策的影响
IJID Reg. 2023 Mar 4;7:110-115. doi: 10.1016/j.ijregi.2023.02.011. eCollection 2023 Jun.
5
HPV screening in the urine of transpeople - A prevalence study.跨性别者尿液中的人乳头瘤病毒筛查——一项患病率研究。
EClinicalMedicine. 2022 Oct 12;54:101702. doi: 10.1016/j.eclinm.2022.101702. eCollection 2022 Dec.

本文引用的文献

1
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
2
First-void urine: A potential biomarker source for triage of high-risk human papillomavirus infected women.首次晨尿:高危型人乳头瘤病毒感染女性分流的潜在生物标志物来源。
Eur J Obstet Gynecol Reprod Biol. 2017 Sep;216:1-11. doi: 10.1016/j.ejogrb.2017.06.036. Epub 2017 Jun 27.
3
Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations.人乳头瘤病毒疫苗:世界卫生组织立场文件,2017年5月 - 建议
Vaccine. 2017 Oct 13;35(43):5753-5755. doi: 10.1016/j.vaccine.2017.05.069. Epub 2017 Jun 5.
4
Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial.9至14岁女孩中两剂人乳头瘤病毒16/18 AS04佐剂疫苗接种方案的持续免疫原性:一项随机试验。
J Infect Dis. 2017 Jun 1;215(11):1711-1719. doi: 10.1093/infdis/jix154.
5
Evaluation of the performance of Human Papillomavirus testing in paired urine and clinician-collected cervical samples among women aged over 30 years in Bhutan.不丹30岁以上女性配对尿液样本与临床医生采集的宫颈样本中人乳头瘤病毒检测性能评估
Virol J. 2017 Apr 8;14(1):74. doi: 10.1186/s12985-017-0744-2.
6
Long-Term Follow-up of HPV Infection Using Urine and Cervical Quantitative HPV DNA Testing.使用尿液和宫颈定量HPV DNA检测对HPV感染进行长期随访
Int J Mol Sci. 2016 May 17;17(5):750. doi: 10.3390/ijms17050750.
7
Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda.在不丹和卢旺达进行尿液检测以监测人乳头瘤病毒(HPV)疫苗接种的影响。
Int J Cancer. 2016 Aug 1;139(3):518-26. doi: 10.1002/ijc.30092. Epub 2016 Apr 15.
8
Less than 3 doses of the HPV vaccine - Review of efficacy against virological and disease end points.少于3剂人乳头瘤病毒疫苗——针对病毒学和疾病终点的疗效综述
Hum Vaccin Immunother. 2016 Jun 2;12(6):1394-402. doi: 10.1080/21645515.2016.1146429. Epub 2016 Mar 2.
9
Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.比较9至14岁女孩人乳头瘤病毒16/18 AS04佐剂疫苗两剂接种方案与15至25岁女性三剂接种方案的随机开放试验。
J Infect Dis. 2016 Aug 15;214(4):525-36. doi: 10.1093/infdis/jiw036. Epub 2016 Feb 3.
10
Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study.印度女孩接种一剂、两剂和三剂四价人乳头瘤病毒疫苗后的免疫原性和人乳头瘤病毒感染:一项多中心前瞻性队列研究
Lancet Oncol. 2016 Jan;17(1):67-77. doi: 10.1016/S1470-2045(15)00414-3. Epub 2015 Dec 2.